Mylan (MYL) Launches Generic Lithobid Tablets for Bipolar Disorder
Tweet Send to a FriendGet Alerts MYL Hot Sheet
Down)
Trade MYL Now!
Mylan Inc. (Nasdaq: MYL) has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Lithium Carbonate Extended-release Tablets USP, 300 mg. This product is the generic version of Noven Therapeutic's Lithobid Tablets, which are indicated for the treatment of manic episodes of bipolar disorder and as a maintenance treatment for individuals with a diagnosis of bipolar disorder.
Lithium Carbonate Extended-release Tablets USP, 300 mg, had U.S. sales of approximately $21 million for the 12 months ending March 31, 2012, according to IMS Health. Mylan is shipping this product immediately.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Lithium Carbonate Extended-release Tablets USP, 300 mg, had U.S. sales of approximately $21 million for the 12 months ending March 31, 2012, according to IMS Health. Mylan is shipping this product immediately.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Merck (MRK) Says Efficacy Not Achieved in Preladenant Phase 3s; Will Discontinue
- St. Jude Medical (STJ) Issues Encouraging Update for EnligHTN™ Multi-Electrode Renal Denervation System Following One Year
- Cardiovascular Systems (CSII) ORBIT II Trial Met Endpoints
Create E-mail Alert Related Categories
Corporate News, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
